Prodotti News Qualità, Privacy & Sicurezza Oncoematologia Diasorin IAM – LIASON IAM BCR-ABL Kit (Qualitative) An ultra rapid molecular solution for one-step differential detection of BCR-ABL common and rare fusion transcripts. The BCR-ABL fusion gene codes for an oncogenic protein with elevated tyrosine kinase activity, which is responsible for the neoplastic transformation. The timely and accurate molecular detection of the BCR-ABL transcripts is mandatory in order to diagnose Philadelphia Positive Leukemias allowing implementation of targeted therapies, which are able to selectively inactivate the BCR-ABL chimeric protein. Brochure IAM PML-RARA Kit An ultra rapid molecular solution for one-step differential detection of BCR-ABL common and rare fusion transcripts. The BCR-ABL fusion gene codes for an oncogenic protein with elevated tyrosine kinase activity, which is responsible for the neoplastic transformation. The timely and accurate molecular detection of the BCR-ABL transcripts is mandatory in order to diagnose Philadelphia Positive Leukemias allowing implementation of targeted therapies, which are able to selectively inactivate the BCR-ABL chimeric protein. Brochure IAM AML1-ETO Kit AML1-ETO/t (8;21)(q22;q22)/ RUNX1-RUNX1T1 is a recurrent genetic abnormality in both childhood and adult Acute Myeloid Leukemia (5-10% of all AML and nearly 40% of the AML FAB M2 subtype). Although this translocation is associated with a good prognosis, only 50% of patients are cured and its rapid molecular identification is crucial for risk stratification of patients and therapeutic decisions. Brochure IAM CBFB_MYH11 Kit CBFB-MYH11, also known as PEBP2B-MYH11, inv(16), t(16;16) is a recurrent genetic abnormality especially in adult Acute Myeloid Leukemia (10% of all de novo AML). This translocation is also one of the most frequently balanced chromosomal translocations found in patients with therapy-related AML (t-AML). Although this genetic alteration is associated with a good prognosis, 30%-40% of these patients experience relapse and its rapid molecular identification is considered crucial for patients’ management and therapeutic decisions. Dati Aziendali Elettrobiochimica s.r.l. Sede Legale: Via Pietro Ottoboni 110, 00159 Roma P. IVA: 01026251007 C.F: 02041690583 GDPR & Sicurezza Privacy: GDPR nuova informativa sulla Privacy ai sensi dell’art. 13 del Regolamento UE 2016/679 Sicurezza: Regolamento sulla sicurezza DVR ai sensi del D. Lgs. 9 Aprile 2008 n. 81 Codice Etico: La società Elettrobiochimica S.r.L. comunica che, ai fini della maggiore trasparenza, si è dotata del Modello di Organizzazione Gestione e Controllo di cui al D.lgs. 8 giugno 2001, n. 231 e sue successive modifiche ( M.O.G.C. ). Inoltre, per gli stessi fini, ha adottato il Codice Etico, parte integrante del medesimo M.O.G.C., scaricabile qui